Premium
Nonviral liver disease is the leading indication for liver transplant in the United States in persons living with human immunodeficiency virus
Author(s) -
CamposVarela Isabel,
Dodge Jennifer L.,
Terrault Norah A.,
Brandman Danielle,
Price Jennifer C.
Publication year - 2021
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.16569
Subject(s) - serostatus , medicine , liver transplantation , transplantation , human immunodeficiency virus (hiv) , liver disease , immunology , gastroenterology , viral load
We evaluated whether indications for liver transplantation (LT) have changed among people with/without human immunodeficiency virus (HIV) infection and compared LT outcomes and trends by HIV serostatus. LT recipients (2008–2018) from the United Network for Organ Sharing and Organ Procurement and Transplantation Network (UNOS/OPTN) were identifed. Among 62 195 LT recipients, 352 (0.6%) were HIV‐infected. The proportion of HIV‐infected patients increased over time ( P trend = .001), as did the number of transplant centers performing LT for HIV‐infected recipients; average annual percentage change of 9.2% ( p < .001). Nonviral causes became the leading indication in 2015 for HIV‐uninfected and in 2018 for HIV‐infected ( P trend < .001). Three‐year cumulative patient survival rates were 77.5%, for HIV‐infected and 84.6%, for HIV‐uninfected ( p = .15). Over time, graft and patient survival rates improved for both HIV‐infected and uninfected ( p < .001). Among HCV‐infected LT recipients, 3‐year patient survival rates were 72.5% for HIV‐infected and 81.8% for HIV‐uninfected ( p = .02). However, in a subanalysis restricted to 2014–2018, differences in graft and patient survival by HIV serostatus were no longer observed (3‐year patient survival rates were 81.2% for HIV‐infected and 86.4% for HIV‐uninfected, p = .34). In conclusion, in the United States, nonviral liver disease is now the leading indication for LT in HIV‐infected patients, and posttransplant outcomes have improved over time.